Overview Financials News + Filings Key Docs Charts Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Cert. of designation
Quarterly results
Appointed COO
Appointed director
|
|
Perspective Therapeutics, Inc. (ISR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 09/28/2022 |
8-K
| Quarterly results|
Docs:
|
"Isoray Announces Transformational Merger and Fourth Quarter and Full-Year Fiscal Year End 2022 Financial Results RICHLAND, WASHINGTON – September 28, 2022 – Isoray, Inc. , a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. Under the terms of the agreement, a newly formed wholly owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint becoming a wholly owned subsidiary of Isoray. At the effective time of the merger, each issued and outstanding share of common stock of Viewpoint will be converted into the right to receive 3.3212 shares of ...",
"Isoray To Announce Fourth Quarter and Fiscal Year End 2022 Financial Results on September 28, 2022" |
|
| 05/10/2022 |
8-K
| Quarterly results |
| 02/08/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"September 30, June 30, 2021 2021 ASSETS Current assets: Cash and cash equivalents $ 61,690 $ 63,828 Accounts receivable, net 1,902 2,013 Inventory 1,060 980 Prepaid expenses and other current assets 306 481 Total current assets 64,958 67,302 Property and equipment, net 1,953 1,958 Right of use asset, net 705 768 Restricted cash 182 182 Inventory, non-current 792 76 Other assets, net 120 130 Total assets $ 68,710 $ 70,416 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 768 $ 730 Lease liability 256 252 Accrued protocol expense 120 98 Accrued radioactive waste disposal 102 100 Accrued payroll and related taxes 300 362 Accrued vacation 253 259 Total current liabilities 1,799 1,801 Non-current liabilities: Lease liability, non-current 459 524 A...",
"Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021" |
|
| 09/21/2021 |
8-K
| Quarterly results |
| 05/13/2021 |
8-K
| Quarterly results |
| 02/09/2021 |
8-K
| Quarterly results |
| 11/10/2020 |
8-K
| Quarterly results |
| 09/17/2020 |
8-K
| Quarterly results |
| 05/12/2020 |
8-K
| Quarterly results |
| 02/11/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 09/24/2019 |
8-K
| Quarterly results|
Docs:
|
"June 30, June 30, 2019 2018 ASSETS Current assets: Cash and cash equivalents $ 5,326 $ 2,600 Short-term investments - 825 Accounts receivable, net 1,154 1,192 Inventory 530 494 Prepaid expenses and other current assets 305 335 Total current assets 7,315 5,446 Property and equipment, net 1,609 1,311 Restricted cash 181 181 Inventory, non-current 155 319 Other assets, net of accumulated amortization 162 198 Total assets $ 9,422 $ 7,455 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 683 $ 1,391 Accrued protocol expense 133 77 Accrued radioactive waste disposal 74 37 Accrued payroll and related taxes 89 155 Accrued vacation 142 175 Total current liabilities 1,121 1,835 Non-current liabilities: Asset retirement obligation 621 590 Total liabilit...",
"Isoray To Announce Fourth Quarter and Year End 2019 Financial Results on September 24, 2019" |
|
| 05/09/2019 |
8-K
| Quarterly results |
| 02/12/2019 |
8-K
| Quarterly results |
| 11/08/2018 |
8-K
| Quarterly results |
| 09/25/2018 |
8-K
| Quarterly results|
Docs:
|
"Professional Services Agreement, between IsoRay Medical, Inc. and J. Squared Partners, Inc., DBA Global IR Group",
"Services Agreement, between IsoRay Medical, Inc. and Schultz Public Relations, LLC",
"ASSETS Current assets: Cash and cash equivalents $ 2,600 $ 5,932 Certificates of deposit 825 3,039 Accounts receivable, net 1,192 726 Inventory 516 323 Prepaid expenses and other current assets 335 271 Total current assets 5,468 10,291 Property and equipment, net 1,311 1,054 Certificates of deposit, non-current - - Restricted cash 181 181 Inventory, non-current 297 513 Other assets, net of accumulated amortization 198 230 Total assets $ 7,455 $ 12,269 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 1,391 $ 630 Accrued protocol expense 77 75 Accrued radioactive waste disposal 37 125 Accrued payroll and related taxes 155 138 Accrued vacation 175 138 Total current liabilities 1,835 1,106 Long-term liabilities: Warrant derivative liability - - ...",
"IsoRay To Announce Fourth Quarter and Year End 2018 Financial Results on September 25, 2018" |
|
| 05/03/2018 |
8-K
| Quarterly results |
| 02/08/2018 |
8-K
| Quarterly results|
Docs:
|
"IsoRay Announces Second Quarter Fiscal 2018 Revenue of $1.54 Million, 50% Second Quarter-Over-Second Quarter Increase",
"IsoRay Announces Second Quarter Fiscal 2018 Earnings Conference Call",
"Safe Harbor Statement Statements in this news release about IsoRay’ s future expectations, including: the advantages of Cesium-131 over iodine, whether interest in and use of our products for brain treatments will increase or continue, continued positive industry data fueling renewed interest in brachytherapy and Cesium-131 for brain treatments, strong patient results, the perception by patients of quality of life outcomes, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ulti..." |
|
| 11/14/2017 |
8-K
| Quarterly results |
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 02/08/2017 |
8-K
| Form 8-K - Current report |
| 11/08/2016 |
8-K
| Form 8-K - Current report |
| 09/08/2016 |
8-K
| Form 8-K - Current report |
| 02/10/2016 |
8-K
| Form 8-K - Current report |
| 11/10/2015 |
8-K
| Form 8-K - Current report |
| 09/15/2015 |
8-K
| Form 8-K - Current report |
| 05/18/2015 |
8-K
| Form 8-K - Current report |
| 02/18/2015 |
8-K
| Form 8-K - Current report |
| 11/17/2014 |
8-K
| Form 8-K - Current report |
| 09/30/2014 |
8-K
| Form 8-K - Current report |
| 05/16/2014 |
8-K
| Form 8-K - Current report |
|
|
|